Rapport Therapeutics (RAPP) announced that it has commenced an underwritten public offering of $250M of shares of its common stock. Goldman Sachs & Co. LLC, Jefferies, TD Cowen and Stifel are acting as joint book-running managers for the proposed offering.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Rapport Therapeutics price target raised to $56 from $35 at Stifel
- EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
- Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX
- Rapport Therapeutics price target raised to $34 from $31 at H.C. Wainwright
- Rapport Therapeutics Reports Positive Phase 2a Trial Results